Flexion Therapeutics (NASDAQ:FLXN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday. The firm presently has a $18.00 price objective on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s target price suggests a potential upside of 14.29% from the stock’s current price.

According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. “

A number of other brokerages have also recently issued reports on FLXN. BidaskClub raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 15th. ValuEngine cut shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 21st. Finally, Wells Fargo & Co set a $39.00 price objective on shares of Flexion Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $34.80.

Shares of NASDAQ FLXN traded up $0.01 during midday trading on Thursday, reaching $15.75. The stock had a trading volume of 374,700 shares, compared to its average volume of 624,015. The company has a debt-to-equity ratio of 1.02, a current ratio of 8.88 and a quick ratio of 8.74. The stock has a market cap of $595.86 million, a PE ratio of -3.79 and a beta of 1.18. Flexion Therapeutics has a 12-month low of $13.36 and a 12-month high of $29.10.

Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Wednesday, November 7th. The specialty pharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.24) by $0.09. The firm had revenue of $6.99 million during the quarter, compared to analysts’ expectations of $5.93 million. Flexion Therapeutics had a negative net margin of 1,346.87% and a negative return on equity of 88.21%. On average, research analysts expect that Flexion Therapeutics will post -4.64 EPS for the current year.

In related news, insider Michael D. Clayman bought 5,000 shares of the business’s stock in a transaction that occurred on Friday, November 9th. The stock was bought at an average cost of $17.10 per share, with a total value of $85,500.00. Following the completion of the purchase, the insider now owns 83,295 shares of the company’s stock, valued at approximately $1,424,344.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO David Arkowitz bought 4,000 shares of the business’s stock in a transaction that occurred on Friday, November 9th. The shares were bought at an average cost of $16.56 per share, with a total value of $66,240.00. Following the completion of the purchase, the chief financial officer now directly owns 48,250 shares of the company’s stock, valued at approximately $799,020. The disclosure for this purchase can be found here. Company insiders own 14.59% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of FLXN. State Board of Administration of Florida Retirement System grew its stake in shares of Flexion Therapeutics by 22.9% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 15,896 shares of the specialty pharmaceutical company’s stock worth $411,000 after buying an additional 2,960 shares in the last quarter. Redmile Group LLC grew its stake in shares of Flexion Therapeutics by 33.5% in the 2nd quarter. Redmile Group LLC now owns 13,260 shares of the specialty pharmaceutical company’s stock worth $343,000 after buying an additional 3,330 shares in the last quarter. Alps Advisors Inc. grew its stake in shares of Flexion Therapeutics by 8.5% in the 2nd quarter. Alps Advisors Inc. now owns 54,622 shares of the specialty pharmaceutical company’s stock worth $1,412,000 after buying an additional 4,272 shares in the last quarter. Dupont Capital Management Corp grew its stake in shares of Flexion Therapeutics by 15.9% in the 3rd quarter. Dupont Capital Management Corp now owns 31,688 shares of the specialty pharmaceutical company’s stock worth $593,000 after buying an additional 4,354 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. grew its stake in shares of Flexion Therapeutics by 3.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 179,658 shares of the specialty pharmaceutical company’s stock worth $4,645,000 after buying an additional 5,257 shares in the last quarter.

About Flexion Therapeutics

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Featured Article: What is the Coverage Ratio?

Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.